Jump to content

Chromium(III) picolinate: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Citation bot (talk | contribs)
Bots
5,241,051 edits
m Citation maintenance. [71]Added: last2, first2, last3, first3, last4, first4, last5, first5. Formatted: pmc. Rjwilmsi
Line 19: Line 19:


==Health claims and debates==
==Health claims and debates==
{{nutshell| There is little reliable evidence for health benefits from chromium picolinate.}}
A pilot trial of 15 patients suggested that chromium picolinate might have antidepressant effects in [[atypical depression]].<ref name="JRDavidson ">{{cite journal | author=Davidson JR, Abraham K, Connor KM, McLeod MN | title=Effectiveness of chromium in atypical depression: a placebo-controlled trial | journal=Biological Psychiatry | volume=53 | issue=3 | year=2003 | pages=261–264 | pmid=12559660 | doi=10.1016/S0006-3223(02)01500-7}}</ref> A larger follow-up trial failed to reproduce this effect, but indicated that the use of chromium picolinate could help to reduce carbohydrate cravings and regulate appetite in these patients.<ref name="JPDocherty">{{cite journal |author=Docherty JP, Sack DA, Roffman M, Finch M, Komorowski JR |title=A double-blind, placebo-controlled, exploratory trial of chromium picolinate in atypical depression: effect on carbohydrate craving |journal=J Psychiatr Pract |volume=11 |issue=5 |pages=302–14 |year=2005 |month=September |pmid=16184071 |doi=10.1097/00131746-200509000-00004}}</ref> A [[post-hoc analysis]] of a subpopulation of patients in this study that experienced high carbohydrate cravings suggested that patients treated with chromium picolinate experienced significant improvements in their depression (as measured by the 29-item [[Hamilton Depression Rating Scale]]) compared to those treated with a [[placebo]]. A more recent study focused on the effects of chromium picolinate supplementation on food intake and satiety. It indicated that chromium supplementation led to reduced cravings for fat, not carbohydrates.<ref>{{cite journal |author=Anton SD, Morrison CD, Cefalu WT, ''et al.'' |title=Effects of chromium picolinate on food intake and satiety |journal=Diabetes Technol. Ther. |volume=10 |issue=5 |pages=405–12 |year=2008 |month=October |pmid=18715218 |pmc=2753428 |doi=10.1089/dia.2007.0292}}</ref>
A pilot trial of 15 patients suggested that chromium picolinate might have antidepressant effects in [[atypical depression]].<ref name="JRDavidson ">{{cite journal | author=Davidson JR, Abraham K, Connor KM, McLeod MN | title=Effectiveness of chromium in atypical depression: a placebo-controlled trial | journal=Biological Psychiatry | volume=53 | issue=3 | year=2003 | pages=261–264 | pmid=12559660 | doi=10.1016/S0006-3223(02)01500-7}}</ref> A larger follow-up trial failed to reproduce this effect, but indicated that the use of chromium picolinate could help to reduce carbohydrate cravings and regulate appetite in these patients.<ref name="JPDocherty">{{cite journal |author=Docherty JP, Sack DA, Roffman M, Finch M, Komorowski JR |title=A double-blind, placebo-controlled, exploratory trial of chromium picolinate in atypical depression: effect on carbohydrate craving |journal=J Psychiatr Pract |volume=11 |issue=5 |pages=302–14 |year=2005 |month=September |pmid=16184071 |doi=10.1097/00131746-200509000-00004}}</ref> A [[post-hoc analysis]] of a subpopulation of patients in this study that experienced high carbohydrate cravings suggested that patients treated with chromium picolinate experienced significant improvements in their depression (as measured by the 29-item [[Hamilton Depression Rating Scale]]) compared to those treated with a [[placebo]]. A more recent study focused on the effects of chromium picolinate supplementation on food intake and satiety. It indicated that chromium supplementation led to reduced cravings for fat, not carbohydrates.<ref>{{cite journal |author=Anton SD, Morrison CD, Cefalu WT, ''et al.'' |title=Effects of chromium picolinate on food intake and satiety |journal=Diabetes Technol. Ther. |volume=10 |issue=5 |pages=405–12 |year=2008 |month=October |pmid=18715218 |pmc=2753428 |doi=10.1089/dia.2007.0292}}</ref>


Revision as of 22:01, 10 January 2010

Chromium(III) picolinate
Chromium(III) picolinate
Names
IUPAC name
Chromium(III) picolinate
Identifiers
ECHA InfoCard 100.131.423 Edit this at Wikidata
Properties
Cr(C6H4NO2)3
Molar mass 418.33 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Chromium(III) picolinate is the chemical compound that is sold as a nutritional supplement to prevent or treat chromium deficiency. This bright-red coordination complex is derived from chromium(III) and picolinic acid. Small quantities of chromium are needed for glucose utilization by insulin in normal health, but deficiency is extremely rare and has only been observed in hospital patients on long-term defined diets.[1] No biochemical basis for the human body's need for chromium has been identified.[2]

Health claims and debates

Template:Nutshell should not be used in articles. Please remove it from this page.

A pilot trial of 15 patients suggested that chromium picolinate might have antidepressant effects in atypical depression.[3] A larger follow-up trial failed to reproduce this effect, but indicated that the use of chromium picolinate could help to reduce carbohydrate cravings and regulate appetite in these patients.[4] A post-hoc analysis of a subpopulation of patients in this study that experienced high carbohydrate cravings suggested that patients treated with chromium picolinate experienced significant improvements in their depression (as measured by the 29-item Hamilton Depression Rating Scale) compared to those treated with a placebo. A more recent study focused on the effects of chromium picolinate supplementation on food intake and satiety. It indicated that chromium supplementation led to reduced cravings for fat, not carbohydrates.[5]

Some commercial organizations promote chromium picolinate as an aid to body development for athletes and as a means of losing weight. But a number of studies have failed to demonstrate an effect of chromium picolinate on either muscle growth or fat loss.[6]

There are claims that the picolinate form of chromium supplementation aids in reducing insulin resistance, particularly in diabetics, but a meta-analysis of chromium supplementation studies showed no association between chromium and glucose or insulin concentrations for non-diabetics, and inconclusive results for diabetics.[7] This study has been challenged on the grounds that it excluded significant results.[8] Subsequent trials gave mixed results, with one finding no effect in people with impaired glucose tolerance,[9] but another seeing a small improvement in glucose resistance.[10] A further study on obese adults with metabolic syndrome, was published in 2009, this found no significant effect on insulin sensitivity, but increased short-term levels of insulin. The study also observed no effect on weight or serum lipids.[11]

In a review of these trials it was again concluded that chromium supplements had no effect on healthy people, but that there might be an improvement in glucose metabolism in diabetics, although the authors stated that the evidence for this effect remains weak.[12] However, opinions differ on this conclusion, a review published in 2006 argued that these data instead supported the clinical efficacy of chromium picolinate for the treatment of diabetes.[13] In 2006, the U.S. Food and Drug Administration stated that the "relationship between chromium picolinate intake and insulin resistance is highly uncertain".[14]

Initial concerns were raised that chromium picolinate is more likely to cause DNA damage and mutation than other forms of trivalent chromium,[15] but these results are also debated.[16] These concerns were based, in part, on studies in fruit flies, where chromium(III) picolinate supplementation generates chromosomal aberrations, impedes progeny development,[17] and causes sterility and lethal mutations.[18] However, other studies indicate that chromium picolinate is safe even at very high doses.[19] In mice, one study observed that chromium(III) picolinate supplementation caused skeletal defects in their offspring.[20] However, a two-year study of the long-term effects of this supplement in rats and mice found no effects on overall survival, or on the animal's body weight and food consumption, the authors of this review also found no evidence that chromium picolinate is carcinogenic.[21]

Regulation

In 2003, the UK Food Standards Agency advised consumers to use other forms of trivalent chromium in preference to chromium picolinate until specialist advice was received from the Committee on Mutagenicity. This was due to concerns about if chromium picolinate might cause cancer (its genotoxicity) raised by the Expert Group on Vitamins and Minerals: the committee also noted two case reports of renal failure that might have been caused by this supplement and called for further research into its safety.[22][23] In December 2004, the Committee on Mutagenicity published its findings, which concluded that "overall it can be concluded that the balance of the data suggest that chromium picolinate should be regarded as not being mutagenic in vitro" and that "the available in-vivo tests in mammals with chromium picolinate are negative.".[24] Following these findings, the UK Food Standards Agency withdrew its advice to avoid chromium picolinate, however it plans to keep its advice about chromium supplements under review.[25]

References

  1. ^ Review of Chromium EXPERT GROUP ON VITAMINS AND MINERALS REVIEW OF CHROMIUM, 12 August 2002
  2. ^ Stearns DM (2000). "Is chromium a trace essential metal?". Biofactors. 11 (3): 149–62. doi:10.1002/biof.5520110301. PMID 10875302.
  3. ^ Davidson JR, Abraham K, Connor KM, McLeod MN (2003). "Effectiveness of chromium in atypical depression: a placebo-controlled trial". Biological Psychiatry. 53 (3): 261–264. doi:10.1016/S0006-3223(02)01500-7. PMID 12559660.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  4. ^ Docherty JP, Sack DA, Roffman M, Finch M, Komorowski JR (2005). "A double-blind, placebo-controlled, exploratory trial of chromium picolinate in atypical depression: effect on carbohydrate craving". J Psychiatr Pract. 11 (5): 302–14. doi:10.1097/00131746-200509000-00004. PMID 16184071. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  5. ^ Anton SD, Morrison CD, Cefalu WT; et al. (2008). "Effects of chromium picolinate on food intake and satiety". Diabetes Technol. Ther. 10 (5): 405–12. doi:10.1089/dia.2007.0292. PMC 2753428. PMID 18715218. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  6. ^ Vincent J.B.; Sack, DA; Roffman, M; Finch, M; Komorowski, JR (2003). "The potential value and toxicity of chromium picolinate as a nutritional supplement, weight loss agent and muscle development agent". Sports Medicine. 33 (3): 213–230. doi:10.2165/00007256-200333030-00004. PMID 16184071.
  7. ^ Althuis MD, Jordan NE, Ludington EA, Wittes JT (1 July 2002). "Glucose and insulin responses to dietary chromium supplements: a meta-analysis". American Journal of Clinical Nutrition. 76 (1): 148–155. PMID 12081828.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  8. ^ Kalman DS (1 July 2003). "Chromium picolinate and type 2 diabetes". American Journal of Clinical Nutrition. 78 (1): 192. PMID 12816793.
  9. ^ Gunton JE, Cheung NW, Hitchman R; et al. (2005). "Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profile: a randomized, placebo-controlled, double-blind trial of supplementation in subjects with impaired glucose tolerance". Diabetes Care. 28 (3): 712–3. doi:10.2337/diacare.28.3.712. PMID 15735214. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  10. ^ Singer GM, Geohas J (2006). "The effect of chromium picolinate and biotin supplementation on glycemic control in poorly controlled patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized trial". Diabetes Technol. Ther. 8 (6): 636–43. doi:10.1089/dia.2006.8.636. PMID 17109595.
  11. ^ Iqbal N, Cardillo S, Volger S; et al. (2009). "Chromium Picolinate Does Not Improve Key Features of Metabolic Syndrome in Obese Nondiabetic Adults". Metab Syndr Relat Disord. 7: 143. doi:10.1089/met.2008.0048. PMID 19196082. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  12. ^ Balk EM, Tatsioni A, Lichtenstein AH, Lau J, Pittas AG (2007). "Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials". Diabetes Care. 30 (8): 2154–63. doi:10.2337/dc06-0996. PMID 17519436.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  13. ^ Broadhurst CL, Domenico P (2006). "Clinical studies on chromium picolinate supplementation in diabetes mellitus--a review". Diabetes Technol. Ther. 8 (6): 677–87. doi:10.1089/dia.2006.8.677. PMID 17109600. {{cite journal}}: Unknown parameter |month= ignored (help)
  14. ^ Trumbo PR, Ellwood KC (2006). "Chromium picolinate intake and risk of type 2 diabetes: an evidence-based review by the United States Food and Drug Administration". Nutr. Rev. 64 (8): 357–63. doi:10.1111/j.1753-4887.2006.tb00220.x. PMID 16958312. {{cite journal}}: Unknown parameter |month= ignored (help)
  15. ^ Chaudhary S, Pinkston J, Rabile MM, Van Horn JD (2005). "Unusual reactivity in a commercial chromium supplement compared to baseline DNA cleavage with synthetic chromium complexes". Journal of Inorganic Biochemistry. 99 (3): 787–794. doi:10.1016/j.jinorgbio.2004.12.009. PMID 15708800.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  16. ^ Hininger I, Benaraba R, Osman M, Faure H, Marie Roussel A, Anderson RA (2007). "Safety of trivalent chromium complexes: no evidence for DNA damage in human HaCaT keratinocytes". Free Radic. Biol. Med. 42 (12): 1759–65. doi:10.1016/j.freeradbiomed.2007.02.034. PMID 17512455.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  17. ^ Stallings DM, Hepburn DD, Hannah M, Vincent JB, O'Donnell J (2006). "Nutritional supplement chromium picolinate generates chromosomal aberrations and impedes progeny development in Drosophila melanogaster". Mutat. Res. 610 (1–2): 101–13. doi:10.1016/j.mrgentox.2006.06.019. PMID 16887379.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  18. ^ Hepburn DD, Xiao J, Bindom S, Vincent JB, O'Donnell J (2003). "Nutritional supplement chromium picolinate causes sterility and lethal mutations in Drosophila melanogaster". Proc. Natl. Acad. Sci. U.S.A. 100 (7): 3766–71. doi:10.1073/pnas.0636646100. PMC 152996. PMID 12649323.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  19. ^ Anderson R, Cheng N, Bryden N; et al. (1997). "Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes". Diabetes. 46 (11): 1786–1791. doi:10.2337/diabetes.46.11.1786. PMID 9356027. {{cite journal}}: Cite has empty unknown parameter: |unused_data= (help); Explicit use of et al. in: |author= (help); Text "[1]" ignored (help)CS1 maint: multiple names: authors list (link)
  20. ^ Bailey MM, Boohaker JG, Sawyer RD; et al. (2006). "Exposure of pregnant mice to chromium picolinate results in skeletal defects in their offspring". Birth Defects Res. B Dev. Reprod. Toxicol. 77 (3): 244–9. doi:10.1002/bdrb.20081. PMID p. {{cite journal}}: Check |pmid= value (help); Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  21. ^ Stout MD, Nyska A, Collins BJ; et al. (2009). "Chronic toxicity and carcinogenicity studies of chromium picolinate monohydrate administered in feed to F344/N rats and B6C3F1 mice for 2 years". Food Chem. Toxicol. 47 (4): 729–33. doi:10.1016/j.fct.2009.01.006. PMC 2718538. PMID 19166900. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  22. ^ Safe Upper Levels for Vitamins and Minerals Food Standards Agency - May 2003
  23. ^ Risk assessment: Chromium Expert Group on Vitamins and Minerals, 2003
  24. ^ STATEMENT ON THE MUTAGENICITY OF TRIVALENT CHROMIUM AND CHROMIUM PICOLINATE COM/04/S3 - December 2004
  25. ^ Agency revises chromium picolinate advice Food Standards Agency - 13 December 2004
Retrieved from "https://en.wikipedia.org/w/index.php?title=Chromium(III)_picolinate&oldid=337073897"